Clinical Trial

CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-17.
Trial Details
NCT Number NCT06470841
Lead Sponsor Navy General Hospital, Beijing
Conditions Acute Myeloid Leukemia
Enrollment 85 participants
Start Date 2024-09-20
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2024-08-22